PubMed · 1996 · 104 citations · 23 references
MedicineNuclear MedicineRadiologyDiagnostic ImagingDiagnostic Nuclear MedicineDiagnostic RadiologyBreast Cancer ImagingBreast ImagingBreast PathologyCancer DetectionCancer DiagnosisTumor DetectionBenign Breast Disease EvaluationBreast Biopsy InterpretationBreast Lesion DiagnosisNoninvasive DiagnosticsNoninvasive Imaging DiagnosisNonpalpable Lesion BiopsyPalpable Lesion Biopsy
UNLABELLED: Our goal was to determine the clinical usefulness of 99mTc-sestamibi to identify breast cancer in patients prior to biopsy. METHODS: We studied 66 patients who received 20 mCi 99mTc-sestamibi intravenously. Lateral and anterior planar images were gathered within 30 min of the injection. Only focal increased uptake was interpreted as positive. Confirmatory pathologic diagnoses were obtained within 2 mo. The prevalence of breast cancer in our sample was 54%. RESULTS: We report an overall sensitivity of 83% and specificity of 93% for the diagnosis of breast cancer. In palpable lesions, the sensitivity was of 94% with a specificity of 91%, while in nonpalpable abnormalities the sensitivity was of 64% with a 100% specificity. Six patients with a malignancy had negative scans, four of these lesions were nonpalpable. Only two of 31 patients with benign lesions had an abnormal scan. CONCLUSION: Mammoscintigraphy with 99mTc-sestamibi has high specificity and adequate sensitivity for the noninvasive diagnosis of breast carcinomas.
23
Analysis of cancers missed at screening mammography.
Richard E. Bird, Terry Wallace, Bonnie C. Yankaskas · Radiology · 1992 · 820 citations
Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex.
David Piwnica‐Worms, Mark L. Chiu, Mark Budding et al. · PubMed · 1993 · 517 citations
Medicine, Oncology, Pharmacology +14
The positive predictive value of mammography.
Daniel B. Kopans · American Journal of Roentgenology · 1992 · 419 citations